RIGL लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

बेचें 107397 min ago

@ $1.160

जारी किया गया: 14 Feb 2024 @ 20:05

वापसी: -5.17%

पिछला सिग्नल: Feb 13 - 20:00

पिछला सिग्नल: खरीदें

वापसी: 0.00 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 01:30):

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases...

Stats
आज की मात्रा	351 535
औसत मात्रा	1.47M
बाजार मूल्य	192.92M
EPS	$0 ( 2024-03-05 )
अगली कमाई की तारीख	( $-0.0300 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.86
ATR14	$0.00300 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Rojkjaer Lisa	Buy	187 500	Employee Stock Option (right to buy)
2024-03-27	Rojkjaer Lisa	Buy	0
2024-02-28	Schorno Dean L	Buy	78 500	Employee Stock Option (right to buy)
2024-02-28	Schorno Dean L	Buy	62 500	Employee Stock Option (right to buy)
2024-02-28	Santos David A	Buy	80 000	Employee Stock Option (right to buy)

INSIDER POWER
93.23
Last 98 transactions
Buy: 9 654 000 \| Sell: 304 047

मात्रा सहसंबंध

लंबा: -0.06 (neutral)

छोटा: -0.90 (strong negative)

Signal:(37.777) Neutral

Rigel Pharmaceuticals Inc सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
CRNC	0.963
ROIV	0.959
NLSP	0.958
MLCO	0.954
MOMO	0.954
FXCO	0.951
CTSO	0.949
APAC	0.948
VRDN	0.946
BRAC	0.945

10 सबसे अधिक नकारात्मक सहसंबंध
GRIN	-0.954
PIII	-0.939
RIVN	-0.938
SNPX	-0.925
OP	-0.924
SWAV	-0.923
ZENV	-0.923
LAWS	-0.919
NAKD	-0.916
ENPH	-0.916

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Rigel Pharmaceuticals Inc सहसंबंध - मुद्रा/वस्त्र

-0.15
( neutral )

-0.29
( neutral )

0.00
( neutral )

0.29
( neutral )

Rigel Pharmaceuticals Inc वित्तीय

Annual	2023
राजस्व:	$116.88M
सकल लाभ:	$109.77M (93.92 %)
EPS:	$-0.140

FY	2023
राजस्व:	$116.88M
सकल लाभ:	$109.77M (93.92 %)
EPS:	$-0.140

FY	2022
राजस्व:	$120.24M
सकल लाभ:	$118.49M (98.55 %)
EPS:	$-0.360

FY	2021
राजस्व:	$149.24M
सकल लाभ:	$148.15M (99.27 %)
EPS:	$-0.110

Financial Reports:

No articles found.

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.